Eagle Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
The Sustainability rating for Eagle Pharmaceuticals Inc represents the company's transparency towards the United Nations SDGs. This page is a free E,S&G analysis covering Eagle Pharmaceuticals Inc. The Disclosure rating covers seventeen UN Sustainable Development Goals including: 'Clean Water & Sanitation', 'Climate Action' and 'Partnerships for the Goals'.
Eagle Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.4; made up of an environmental score of 8.0, social score of 6.4 and governance score of 4.8.
6.4
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
389 | WuXi Biologics (Cayman) Inc | 6.6 | High |
401 | Oxford Cannabinoid Technologies Holdings PLC | 6.5 | High |
402 | Eagle Pharmaceuticals Inc | 6.4 | High |
402 | Capricor Therapeutics Inc | 6.4 | High |
402 | Alembic Pharmaceuticals Ltd | 6.4 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Eagle Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does Eagle Pharmaceuticals Inc disclose current and historical energy intensity?
Does Eagle Pharmaceuticals Inc report the average age of the workforce?
Does Eagle Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does Eagle Pharmaceuticals Inc disclose its ethnicity pay gap?
Does Eagle Pharmaceuticals Inc disclose cybersecurity risks?
Does Eagle Pharmaceuticals Inc offer flexible work?
Does Eagle Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Eagle Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does Eagle Pharmaceuticals Inc conduct supply chain audits?
Does Eagle Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Eagle Pharmaceuticals Inc conduct 360 degree staff reviews?
Does Eagle Pharmaceuticals Inc disclose the individual responsible for D&I?
Does Eagle Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Eagle Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does Eagle Pharmaceuticals Inc disclose water use targets?
Does Eagle Pharmaceuticals Inc have careers partnerships with academic institutions?
Did Eagle Pharmaceuticals Inc have a product recall in the last two years?
Does Eagle Pharmaceuticals Inc disclose incidents of discrimination?
Does Eagle Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has Eagle Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does Eagle Pharmaceuticals Inc disclose parental leave metrics?
Does Eagle Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does Eagle Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Eagle Pharmaceuticals Inc disclose the pay ratio of women to men?
Does Eagle Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does Eagle Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Eagle Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Eagle Pharmaceuticals Inc involved in embryonic stem cell research?
Does Eagle Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does Eagle Pharmaceuticals Inc disclose its waste policy?
Does Eagle Pharmaceuticals Inc report according to TCFD requirements?
Does Eagle Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Eagle Pharmaceuticals Inc disclose energy use targets?
Does Eagle Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Eagle Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Eagle Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.